Ipamorelin

Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a) and stimulates the release of growth hormone (GH) from the anterior pituitary gland. Unlike other GH secretagogues, Ipamorelin does not significantly increase levels of adrenocorticotropic hormone (ACTH), cortisol, or prolactin. This selectivity makes Ipamorelin a promising research peptide for studying the effects of GH secretion without the confounding effects of other hormones.

Ipamorelin binds to the GHS-R1a receptor, which is primarily expressed in the hypothalamus and pituitary gland. Upon binding, it triggers a cascade of signaling events that ultimately lead to the synthesis and secretion of GH. The released GH then binds to its receptors in various target tissues, such as the liver, muscle, and bone, to exert its anabolic effects.

Based on research studies, Ipamorelin has demonstrated several potential benefits in animal models:

• Growth hormone secretion: Ipamorelin potently stimulates the release of GH from the pituitary gland, which can help maintain or increase lean body mass, reduce body fat, and improve overall body composition.
• Appetite regulation: Ipamorelin has been shown to regulate appetite and food intake in animal studies, suggesting its potential as a research tool in studying metabolic disorders and obesity.
• Bone health: GH plays a crucial role in maintaining bone mineral density and strength. Ipamorelin-induced GH secretion may have potential benefits for bone health, as demonstrated in animal studies.
• Cardiovascular function: Some studies have indicated that Ipamorelin may have positive effects on cardiovascular function, such as improving left ventricular function and reducing systemic vascular resistance in animal models.
• Anti-aging effects: GH levels decline with age, contributing to age-related changes in body composition, bone density, and skin elasticity. Ipamorelin-induced GH secretion may help mitigate some of these age-related changes, as suggested by animal studies.

In animal studies, Ipamorelin appeared to be well-tolerated with minimal side effects.

Note: The safety profile of Ipamorelin has not been fully established, and further clinical studies are needed to fully evaluate the potential for side effects and long-term safety in mammals.

Ipamorelin is a research peptide and selective ghrelin receptor agonist that stimulates the secretion of growth hormone (GH) from the pituitary gland. Animal studies have demonstrated its potential benefits in promoting GH release, regulating appetite, improving body composition, supporting bone health, and enhancing cardiovascular function. Ipamorelin's selectivity for GH secretion without significantly affecting other hormones makes it a promising research tool in the fields of endocrinology, metabolism, and aging. However, further research is needed to fully elucidate its mechanisms of action, potential therapeutic applications, and safety profile in mammalian models.

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
2. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999.
3. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone secretagogue increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998.
4. Ankersen M, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1999.
5. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999.
6. Hansen BS, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999.
7. Pihoker C, et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children. J Clin Endocrinol Metab. 1998.
8. Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998.
9. Bowers CY. Growth hormone-releasing peptide. Cell Mol Life Sci. 1998.
10. Ghigo E, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1997.
11. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984.

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. Neither the products described nor the company are intended to diagnose, treat, cure, or prevent any disease.